Reports Q2 revenue $31.24M, consensus $30.36M. “Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our customers as they navigate an environment with improving, but still elevated, levels of uncertainty related to funding for public health programs and research,” said Carrie Eglinton Manner, president and CEO of OTI.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSUR:
- OraSure Technologies Reports 43% Revenue Decline in Q2 2025
- OraSure appoints Messing as Chief Commercial Officer
- OSUR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OraSure received takeover bid from on Ron Zwanziger, Reuters reports
- OraSure bid between $3.50-$4.00 per share, Reuters says